CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer von Taniguchi, Hiroya, Nakamura, Yoshiaki, Kotani, Daisuke, Yukami, Hiroki, Mishima, Saori, Sawada, Kentaro, Shirasu, Hiromichi, Ebi, Hiromichi, Yamanaka, Takeharu, Aleshin, Alexey, Billings, Paul R., Rabinowitz, Matthew, Oki, Eiji, Takemasa, Ichiro, Kato, Takeshi, Mori, Masaki, Yoshino, Takayuki

Volltext

Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer von Adachi, Yuta, Ito, Kentaro, Hayashi, Yuko, Kimura, Ryo, Tan, Tuan Zea, Yamaguchi, Rui, Ebi, Hiromichi

Volltext

Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial von Nakamura, Yoshiaki, Okamoto, Wataru, Kato, Takeshi, Esaki, Taito, Kato, Ken, Komatsu, Yoshito, Yuki, Satoshi, Masuishi, Toshiki, Nishina, Tomohiro, Ebi, Hiromichi, Sawada, Kentaro, Taniguchi, Hiroya, Fuse, Nozomu, Nomura, Shogo, Fukui, Makoto, Matsuda, Seiko, Sakamoto, Yasutoshi, Uchigata, Hiroshi, Kitajima, Kana, Kuramoto, Naomi, Asakawa, Takashi, Olsen, Steve, Odegaard, Justin I., Sato, Akihiro, Fujii, Satoshi, Ohtsu, Atsushi, Yoshino, Takayuki

Volltext

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK von Katayama, Ryohei, Khan, Tahsin M., Benes, Cyril, Lifshits, Eugene, Ebi, Hiromichi, Rivera, Victor M., Shakespeare, William C., Iafrate, A. John, Engelman, Jeffrey A., Shaw, Alice T., Vogt, Peter K.

Volltext

Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition von Ebi, Hiromichi, Bando, Hideaki, Taniguchi, Hiroya, Sunakawa, Yu, Okugawa, Yoshinaga, Hatanaka, Yutaka, Hosoda, Waki, Kumamoto, Kensuke, Nakatani, Kaname, Yamazaki, Kentaro

Volltext

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer von Kitai, Hidenori, Ebi, Hiromichi, Tomida, Shuta, Floros, Konstantinos V, Kotani, Hiroshi, Adachi, Yuta, Oizumi, Satoshi, Nishimura, Masaharu, Faber, Anthony C, Yano, Seiji

Volltext

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers von Adachi, Yuta, Kimura, Ryo, Hirade, Kentaro, Ebi, Hiromichi

Volltext

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1 von Ebi, Hiromichi, Costa, Carlotta, Faber, Anthony C., Nishtala, Madhuri, Kotani, Hiroshi, Juric, Dejan, Pelle, Patricia Della, Song, Youngchul, Yano, Seiji, Mino-Kenudson, Mari, Benes, Cyril H., Engelman, Jeffrey A.

Volltext

Drug-Tolerant Persister Cells After EGFR Tyrosine Kinase Inhibitor Treatment: Their Origin and the Influences From the Tumor Microenvironment von Ebi, Hiromichi

Volltext

Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models von Corcoran, Ryan B., Cheng, Katherine A., Hata, Aaron N., Faber, Anthony C., Ebi, Hiromichi, Coffee, Erin M., Greninger, Patricia, Brown, Ronald D., Godfrey, Jason T., Cohoon, Travis J., Song, Youngchul, Lifshits, Eugene, Hung, Kenneth E., Shioda, Toshi, Dias-Santagata, Dora, Singh, Anurag, Settleman, Jeffrey, Benes, Cyril H., Mino-Kenudson, Mari, Wong, Kwok-Kin, Engelman, Jeffrey A.

Volltext

SY21-4 Mechanisms of resistance to RAS-targeting therapies von Ebi, Hiromichi

Volltext

The ADAM17 protease promotes tobacco smoke carcinogen-induced lung tumorigenesis von Saad, Mohamed I, McLeod, Louise, Yu, Liang, Ebi, Hiromichi, Ruwanpura, Saleela, Sagi, Irit, Rose-John, Stefan, Jenkins, Brendan J

Volltext

Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer von Lin, Yingsong, Nakatochi, Masahiro, Hosono, Yasuyuki, Ito, Hidemi, Kamatani, Yoichiro, Inoko, Akihito, Sakamoto, Hiromi, Kinoshita, Fumie, Kobayashi, Yumiko, Ishii, Hiroshi, Ozaka, Masato, Sasaki, Takashi, Matsuyama, Masato, Sasahira, Naoki, Morimoto, Manabu, Kobayashi, Satoshi, Fukushima, Taito, Ueno, Makoto, Ohkawa, Shinichi, Egawa, Naoto, Kuruma, Sawako, Mori, Mitsuru, Nakao, Haruhisa, Adachi, Yasushi, Okuda, Masumi, Osaki, Takako, Kamiya, Shigeru, Wang, Chaochen, Hara, Kazuo, Shimizu, Yasuhiro, Miyamoto, Tatsuo, Hayashi, Yuko, Ebi, Hiromichi, Kohmoto, Tomohiro, Imoto, Issei, Kasugai, Yumiko, Murakami, Yoshinori, Akiyama, Masato, Ishigaki, Kazuyoshi, Matsuda, Koichi, Hirata, Makoto, Shimada, Kazuaki, Okusaka, Takuji, Kawaguchi, Takahisa, Takahashi, Meiko, Watanabe, Yoshiyuki, Kuriki, Kiyonori, Kadota, Aya, Okada, Rieko, Mikami, Haruo, Takezaki, Toshiro, Suzuki, Sadao, Yamaji, Taiki, Iwasaki, Motoki, Sawada, Norie, Goto, Atsushi, Kinoshita, Kengo, Fuse, Nobuo, Katsuoka, Fumiki, Shimizu, Atsushi, Nishizuka, Satoshi S., Tanno, Kozo, Suzuki, Ken, Okada, Yukinori, Horikoshi, Momoko, Yamauchi, Toshimasa, Kadowaki, Takashi, Yu, Herbert, Zhong, Jun, Amundadottir, Laufey T., Doki, Yuichiro, Ishii, Hideshi, Eguchi, Hidetoshi, Bogumil, David, Haiman, Christopher A., Le Marchand, Loic, Mori, Masaki, Risch, Harvey, Setiawan, Veronica W., Tsugane, Shoichiro, Wakai, Kenji, Yoshida, Teruhiko, Matsuda, Fumihiko, Kubo, Michiaki, Kikuchi, Shogo, Matsuo, Keitaro

Volltext

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers von Ebi, Hiromichi, Corcoran, Ryan B, Singh, Anurag, Chen, Zhao, Song, Youngchul, Lifshits, Eugene, Ryan, David P, Meyerhardt, Jeffrey A, Benes, Cyril, Settleman, Jeffrey, Wong, Kwok-Kin, Cantley, Lewis C, Engelman, Jeffrey A

Volltext

Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients von Taniguchi, Hiroya, Yamazaki, Kentaro, Yoshino, Takayuki, Muro, Kei, Yatabe, Yasushi, Watanabe, Toshiaki, Ebi, Hiromichi, Ochiai, Atsushi, Baba, Eishi, Tsuchihara, Katsuya

Volltext

Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition von Yamazaki, Kentaro, Taniguchi, Hiroya, Yoshino, Takayuki, Akagi, Kiwamu, Ishida, Hideyuki, Ebi, Hiromichi, Nakatani, Kaname, Muro, Kei, Yatabe, Yasushi, Yamaguchi, Kensei, Tsuchihara, Katsuya

Volltext

ADAM17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer von Saad, Mohamed I, Alhayyani, Sultan, McLeod, Louise, Yu, Liang, Alanazi, Mohammad, Deswaerte, Virginie, Tang, Ke, Jarde, Thierry, Smith, Julian A, Prodanovic, Zdenka, Tate, Michelle D, Balic, Jesse J, Watkins, D Neil, Cain, Jason E, Bozinovski, Steven, Algar, Elizabeth, Kohmoto, Tomohiro, Ebi, Hiromichi, Ferlin, Walter, Garbers, Christoph, Ruwanpura, Saleela, Sagi, Irit, Rose‐John, Stefan, Jenkins, Brendan J

Volltext

Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR -Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target von Song, Kyung-A, Hosono, Yasuyuki, Turner, Crystal, Jacob, Sheeba, Lochmann, Timothy L, Murakami, Yoshiko, Patel, Neha U, Ham, Jungoh, Hu, Bin, Powell, Krista M, Coon, Colin M, Windle, Brad E, Oya, Yuko, Koblinski, Jennifer E, Harada, Hisashi, Leverson, Joel D, Souers, Andrew J, Hata, Aaron N, Boikos, Sosipatros, Yatabe, Yasushi, Ebi, Hiromichi, Faber, Anthony C

Volltext

Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer von Kitai, Hidenori, Choi, Philip H., Yang, Yu C., Boyer, Jacob A., Whaley, Adele, Pancholi, Priya, Thant, Claire, Reiter, Jason, Chen, Kevin, Markov, Vladimir, Taniguchi, Hirokazu, Yamaguchi, Rui, Ebi, Hiromichi, Evans, James, Jiang, Jingjing, Lee, Bianca, Wildes, David, de Stanchina, Elisa, Smith, Jacqueline A. M., Singh, Mallika, Rosen, Neal

Volltext

Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report von Maeda, Akimitsu, Irie, Kei, Hashimoto, Naoya, Fukushima, Shoji, Ando, Hitoshi, Okada, Akira, Ebi, Hiromichi, Kajita, Masaki, Iwata, Hiroji, Sawaki, Masataka

Volltext